New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
09:21 EDTRT, HPQ, QLYS, EBAY, CSH, RAD, FEYE, PIR, MRK, BBBY, IMPVOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Rite Aid (RAD), up 13%... Ruby Tuesday (RT), up 7%... Pier 1 Imports (PIR), up 4%. ALSO HIGHER: Merck (MRK), up 1.5% after announcing data from C-WORTHy study... Cash America (CSH), up 15% after earnings report, announcing plans to evaluate separation of online business... HP (HPQ), up 1.7% after initiated with a Buy at Deutsche Bank. DOWN AFTER EARNINGS: Bed Bath & Beyond (BBBY), down 5.3%. ALSO LOWER: EBAY (EBAY), down 1% after settling proxy contest with Carl Icahn, who withdrew his PayPal spin-off proposal... Imperva (IMPV), down 35% after slashing its first quarter profit and sales outlook, shares downgraded at Deutsche Bank and Oppenheimer. Several of its security software peers are lower in pre-market trade as well, including FireEye (FEYE), which is down 3%, and Qualys (QLYS), which is down 1.5%.
News For EBAY;IMPV;FEYE;QLYS;BBBY;RAD;HPQ;MRK;CSH;RT;PIR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
February 23, 2015
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGM’s most recent financing. Merck will commit up to $250M to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
06:21 EDTEBAYFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
06:06 EDTRADStocks with implied volatility movement; JNJ NUGT
Stocks with implied volatility movement; Halliburton (HAL) 32, Rite Aid (RAD) 34 according to iVolatility.
February 20, 2015
10:01 EDTCSHOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Advanced Drainage (WMS) initiated with an Outperform at Boenning & Scattergood... Arctic Cat (ACAT) initiated with a Hold at BB&T... Ardmore Shipping (ASC) initiated with an Accumulate at Global Hunter... Baltic Trading (BALT) initiated with a Speculative Buy at Global Hunter... Cash America (CSH) initiated with a Buy at Jefferies... Costamare (CMRE) initiated with an Accumulate at Global Hunter... DHT Holdings (DHT) initiated with a Buy at Global Hunter... Danaos (DAC) initiated with a Neutral at Global Hunter... Diana Containerships (DCIX) initiated with a Neutral at Global Hunter... Diana Shipping (DSX) initiated with a Neutral at Global Hunter... Euronav NV (EURN) initiated with a Buy at Global Hunter... Forest City (FCE.A) initiated with a Neutral at Citigroup... Fox Factory (FOXF) initiated with a Hold at BB&T... Frontline (FRO) initiated with an Accumulate at Global Hunter... Global Ship Lease (GSL) initiated with a Neutral at Global Hunter... GrubHub (GRUB) initiated with an Overweight at Barclays... Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at BMO Capital... Kinder Morgan (KMI) reinstated with an Overweight at Barclays... Liberty Broadband (LBRDA) initiated with an Outperform at FBN Securities... Liberty Interactive (QVCA) initiated with a Sector Perform at FBN Securities... Liberty Media (LMCA) initiated with an Outperform at FBN Securities... MEI Pharma (MEIP) initiated with a Buy at BofA/Merrill... Navios Acquisition (NNA) initiated with a Buy at Global Hunter... Polaris Industries (PII) initiated with a Buy at BB&T... Raven (RAVN) initiated with an Equal Weight at Stephens... Scorpio Bulkers (SALT) initiated with a Speculative Buy at Global Hunter... Scorpio Tankers (STNG) initiated with an Accumulate at Global Hunter... Seaspan (SSW) initiated with a Neutral at Global Hunter... Star Bulk Carriers (SBLK) initiated with a Speculative Buy at Global Hunter... Tsakos Energy (TNP) initiated with a Buy at Global Hunter... U.S. Concrete (USCR) initiated with an Overweight at Stephens.
09:08 EDTFEYEFireEye price target raised to $50 from $44 at UBS
UBS raised its price target on FireEye to $50 from $44 following meetings with management. The firm cited improved business trends, new partnerships and higher state and local government spending. UBS reiterated its Buy rating on FireEye shares.
07:27 EDTHPQHP volatility elevated into Q1 and growth outlook
Subscribe for More Information
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
05:37 EDTCSHCash America initiated with a Buy at Jefferies
Subscribe for More Information
February 19, 2015
12:30 EDTIMPVImperva management to meet with Sterne Agee
Subscribe for More Information
10:25 EDTQLYSQualys and China Biologic mentioned positively by Navellier
Subscribe for More Information
08:45 EDTHPQHP launches open network switches for web scale cloud data centers
Subscribe for More Information
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
February 18, 2015
15:15 EDTEBAYAngie's List could be more attractive to buyers given traction, says Barrington
Subscribe for More Information
11:04 EDTCSHCash America management to meet with Sterne Agee
Subscribe for More Information
10:02 EDTHPQe.Digital Corporation files patent infringement lawsuits against HP, others
Subscribe for More Information
06:15 EDTHPQHP Q1 sales should be in-line despite currency, says Citigroup
Subscribe for More Information
February 17, 2015
17:06 EDTEBAYIcahn gives quarterly update on stakes, takes new stake in Manitowoc
Subscribe for More Information
08:06 EDTIMPVImperva revenue growth set to rebound, says Oppenheimer
After meeting with Imperva's management, Oppenheimer says that the company's focus on salesforce best practices and its good execution should cause its revenue growth to accelerate. The firm adds that demand for the company's products is strong, and it keeps a $55 price target and Outperform rating on the shares.
07:50 EDTFEYEFireEye price target raised to $49 from $44 at BofA/Merrill
BofA/Merrill raised Buy rated FireEye's price target to $49 to reflect expected improvements in cash flow as investment in international infrastructure and M&A slows. The firm continues to view FireEye as a top pick given technological advantages, upside to billings and revenue growth, execution abilities, and strong sector trends.
February 15, 2015
17:43 EDTFEYE, QLYS, IMPVCybersecurity firm Kaspersky warns of cyber attack on banks, FT says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use